LINC01934: A Long Intergenic Non-Protein Coding RNA as a Drug Target or Biomarker

Target Name: LINC01934

NCBI ID: G101927156

LINC01934

Other Name(s): long intergenic non-protein coding RNA 1934 | Long intergenic non-protein coding RNA 1934

LINC01934: A Long Intergenic Non-Protein Coding RNA as a Drug Target or Biomarker

LINC01934 is a long intergenic non-protein coding RNA (lncRNA) that has been identified using RNA sequencing (RNA-seq) data. It is characterized by its unique 3'-end exon, which is usually removed during normal gene expression, and its ability to transcribe from multiple genomic locations. LINC01934 has been shown to play a role in various cellular processes, including cell adhesion, migration, and transcriptional regulation.

Drug Target Potential

The potential drug targets for LINC01934 are numerous and varied. Its unique expression pattern and functions in different cellular contexts make it an attractive target for researchers looking for new therapeutic approaches.

One potential mechanism by which LINC01934 could be a drug target is its role in cell adhesion. LINC01934 has been shown to be involved in the formation of tight junctions, which are critical for maintaining tissue structure and barrier function. By interfering with this process, LINC01934 could be targeted as a treatment for various diseases that involve dysfunction in cell adhesion, such as cancer, neurodegenerative diseases, and autoimmune disorders.

Another potential mechanism for LINC01934 as a drug target is its role in cell migration. LINC01934 has been shown to be involved in the regulation of cell migration, which is a critical process for the development and maintenance of tissues and organs. By targeting LINC01934, researchers could potentially develop new treatments for various types of cancer, neuroimaging contrast agents, and other diseases that involve uncontrolled cell migration.

Biomarker Potential

In addition to its potential as a drug target, LINC01934 also has the potential as a biomarker. Its unique expression pattern and functions make it an attractive target for researchers looking for new diagnostic tools.

One potential use for LINC01934 as a biomarker is its potential to serve as a protein biomarker for cancer. LINC01934 has been shown to be involved in the regulation of various cellular processes that are also involved in cancer development, such as cell adhesion, angiogenesis, and metastasis. By targeting LINC01934 with drugs or other therapeutic approaches, researchers could potentially develop new treatments for various types of cancer.

Another potential use for LINC01934 as a biomarker is its potential to serve as a diagnostic tool for various diseases. LINC01934 has been shown to be involved in the regulation of various cellular processes that are also involved in disease development, such as inflammation, fibrosis, and autophagy. By targeting LINC01934 with diagnostic tools such as RNA-seq or qRT-PCR, researchers could potentially identify new biomarkers for various diseases.

Conclusion

LINC01934 is a long intergenic non-protein coding RNA that has been identified using RNA-seq data. It has been shown to play a role in various cellular processes, including cell adhesion, migration, and transcriptional regulation. Its unique expression pattern and functions make it an attractive target for researchers looking for new therapeutic approaches and biomarkers. As further research is conducted, LINC01934 is likely to continue to emerge as a promising drug target and biomarker for a variety of diseases.

Protein Name: Long Intergenic Non-protein Coding RNA 1934

The "LINC01934 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01934 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets